by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia
Abstract INTRODUCTION The Alzheimer’s Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer’s disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat’s side...
by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia
Abstract The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for...
by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia
Abstract INTRODUCTION We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs). METHODS We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION We examined the burden of Alzheimer’s disease and other dementias (ADOD) and attributable factors at the national and provincial levels in China. METHODS Using the Global Burden of Diseases Study 2021, we estimated incidence, prevalence,...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION Subjective cognitive decline (SCD) may be an early marker of Alzheimer’s disease (AD) pathology. Until recently, it was impossible to measure biomarkers specific for α-synuclein pathology; therefore, its association with subjective reports...
